Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates
- PMID: 6467175
Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates
Abstract
The covalent attachment of monomethoxypolyethylene glycol (PEG) to asparaginases from Escherichia coli and Vibrio succinogenes by new coupling methodology produced conjugates that are active, stable, without significant immune response, and with greatly extended plasma half-lives in mice. Therapeutic efficacies were greater for the PEG-asparaginases than for the unmodified asparaginases in mice infected with the L5178Y lymphosarcoma or the 6C3HED tumor. Large single doses of native or modified enzymes were more effective against tumors than the same amount of enzyme given in smaller doses over several days.
Similar articles
-
Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.Gan. 1982 Jun;73(3):470-4. Gan. 1982. PMID: 6751921
-
Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.Leukemia. 1997 Apr;11 Suppl 3:408-9. Leukemia. 1997. PMID: 9209407
-
Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia.Cancer Biochem Biophys. 1984 Sep;7(3):261-8. Cancer Biochem Biophys. 1984. PMID: 6488153
-
[Antineoplastic effect of L-asparaginase].Postepy Hig Med Dosw. 1981 Mar-Apr;35(2):177-87. Postepy Hig Med Dosw. 1981. PMID: 7038650 Review. Polish. No abstract available.
-
Antitumor enzyme: polyethylene glycol-modified asparaginase.Ann N Y Acad Sci. 1990;613:95-108. doi: 10.1111/j.1749-6632.1990.tb18151.x. Ann N Y Acad Sci. 1990. PMID: 2076022 Review. No abstract available.
Cited by
-
Editorial: Innovative medical technology based on artificial cells, including its different configurations.Front Med Technol. 2023 Nov 10;5:1306419. doi: 10.3389/fmedt.2023.1306419. eCollection 2023. Front Med Technol. 2023. PMID: 38021437 Free PMC article. No abstract available.
-
Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors.Health Phys. 2014 Jan;106(1):21-38. doi: 10.1097/HP.0b013e3182a4df10. Health Phys. 2014. PMID: 24276547 Free PMC article.
-
Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.Cancer Chemother Pharmacol. 1993;32(4):310-4. doi: 10.1007/BF00686177. Cancer Chemother Pharmacol. 1993. PMID: 8324873
-
Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.Jpn J Cancer Res. 1994 Jan;85(1):9-12. doi: 10.1111/j.1349-7006.1994.tb02879.x. Jpn J Cancer Res. 1994. PMID: 8106293 Free PMC article.
-
Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.Br J Cancer. 1996 Feb;73(3):281-7. doi: 10.1038/bjc.1996.50. Br J Cancer. 1996. PMID: 8562331 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources